Nanexa AB (FRA:40M) E10: €-0.08 (As of Mar. 2026)


FRA:40M Nanexa AB FRA:40M
48 GF Score
Price €0.30
GF Value €0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nanexa AB E10?

Nanexa AB FRA:40M -2.89% 48 E10 is €-0.08 as of Mar. 2026. GuruFocus rates FRA:40M with a GF Score™ of 48/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nanexa AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.007. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.08 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), Nanexa AB's current stock price is €0.3025. Nanexa AB's E10 for the quarter that ended in Mar. 2026 was €-0.08. Nanexa AB's Shiller PE Ratio of today is .


Nanexa AB  (FRA:40M) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nanexa AB E10 Related Terms


Nanexa AB E10 Historical Data

* Premium members only.

The historical data trend for Nanexa AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanexa AB E10 Chart

Nanexa AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.08 -0.09

Nanexa AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.08 -0.08 -0.09 -0.08

FRA:40M vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanexa AB Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nanexa AB's Shiller PE Ratio falls into.


FRA:40M
48GF Score
Nanexa AB FRA:40M
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanexa AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nanexa AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.007/133.3862*133.3862
=-0.007

Current CPI (Mar. 2026) = 133.3862.

Nanexa AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.023 101.019 -0.030
201609 -0.016 101.138 -0.021
201612 -0.034 102.022 -0.044
201703 -0.024 102.022 -0.031
201706 -0.028 102.752 -0.036
201709 -0.020 103.279 -0.026
201712 -0.018 103.793 -0.023
201803 -0.018 103.962 -0.023
201806 -0.020 104.875 -0.025
201809 -0.016 105.679 -0.020
201812 -0.034 105.912 -0.043
201903 -0.020 105.886 -0.025
201906 -0.012 106.742 -0.015
201909 -0.014 107.214 -0.017
201912 -0.031 107.766 -0.038
202003 -0.019 106.563 -0.024
202006 -0.030 107.498 -0.037
202009 -0.017 107.635 -0.021
202012 -0.037 108.296 -0.046
202103 -0.029 108.360 -0.036
202106 -0.033 108.928 -0.040
202109 -0.018 110.338 -0.022
202112 -0.025 112.486 -0.030
202203 -0.023 114.825 -0.027
202206 -0.030 118.384 -0.034
202209 -0.022 122.296 -0.024
202212 -0.033 126.365 -0.035
202303 -0.012 127.042 -0.013
202306 -0.014 129.407 -0.014
202309 -0.009 130.224 -0.009
202312 -0.046 131.912 -0.047
202403 -0.002 132.205 -0.002
202406 -0.004 132.716 -0.004
202409 -0.003 132.304 -0.003
202412 -0.008 132.987 -0.008
202503 -0.005 132.825 -0.005
202506 -0.004 133.699 -0.004
202509 -0.007 133.482 -0.007
202512 0.009 133.386 0.009
202603 -0.007 133.386 -0.007

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.08 mean?
Nanexa AB (FRA:40M) has a E10 of €-0.08 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nanexa AB and its competitors.
Is Nanexa AB's E10 too high?
Nanexa AB's current E10 is €-0.08. Overall, Nanexa AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's E10 compare to ZTS?
Nanexa AB's E10 of €-0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nanexa AB and its competitors. Nanexa AB's current E10 is €-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.30 — trading 77.9% above its estimated fair value. The current E10 is €-0.08. Nanexa AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current E10 is €-0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanexa AB (FRA:40M) Overvalued in 2026?

Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued. The current stock price of €0.30 is trading 77.9% above its estimated GF Value™ of €0.17. GuruFocus considers Nanexa AB to be Significantly Overvalued.

Key valuation signals for FRA:40M:

  • E10: €-0.08
  • GF Value™: €0.17 vs. price of €0.30 (77.9% above fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanexa AB Business Description

Other Exchanges NANEXA:Sweden
Address Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
48GF Score

Get the complete analysis for FRA:40M

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€0.17
GF Value